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Cancer is one of the most urgent health
issues of today. According to WHO, the
number of cancer cases is expected to
increase by 75% in the next two decades (1).
Despite some remarkable achievements in
the fields of cancer prevention and early
detection, the goal of developing effective
anti-cancer therapies still remains unmet.
Tumor recurrence due to treatment resis-
tance is the most common cause of death
from cancer. Delineating cellular and mole-
cular mechanisms underlying tumor recur-
rence is of prime importance for the ability
to improve the efficacy of existing thera-
pies and develop new strategies to cancer
treatment.
The aim of any anti-cancer treatment
is to selectively kill cancer cells by tar-
geting key biological properties essential
for the maintenance of tumorigenicity and
malignant progression (2). Currently, cyto-
toxic therapies are still a mainstay of cancer
treatment that relies heavily on radiation
treatment and chemotherapy. Even though
cytotoxic treatments can be effective in
some types of cancers, the clinical experi-
ence accumulated over the past few decades
indicates that conventional cytotoxic ther-
apy may not suffice to achieve a satisfactory
level of the therapeutic efficacy. A con-
ceptual framework for cytotoxic therapies
derives from the observation that there is
a direct relationship between proliferation
rate and cytotoxic sensitivity, implying that
rapidly dividing cancer cells rather than
largely quiescent normal cells should be
preferentially targeted by cytotoxic agents.
However, proliferation rates of tumor cells
can vary in a broad range between and
within tumors. This is thought to be one
of the reasons for insufficient efficacy of
cytotoxic therapies (3). Furthermore, can-
cer cells can neutralize the effects of cyto-
toxic treatments by utilizing a plethora of
often overlapping mechanisms that include
aberrant DNA repair and cell death path-
ways, drug efflux, hypoxia-induced apop-
tosis resistance and invasion, alterations
in drug metabolism, unfolded protein
response, and autophagy [reviewed in Ref.
(4, 5)].
A newer type of anti-cancer therapy
generally called molecularly targeted ther-
apy relies on rationally designed agents to
target, with a high degree of specificity,
well-defined molecules or pathways that
operate in cancer cells to maintain their
malignant potential. Although both cyto-
toxic and molecularly targeted therapeu-
tic approaches generally exploit differences
between neoplastic and normal cells, only
targeted therapies enable the so-called pre-
cision medicine. Recent advances in the
field of molecular profiling have opened up
a real possibility to make better informed
treatment decisions based on the data from
personalized tumor profiling [reviewed in
Ref. (6, 7)]. However, despite some remark-
able successes of targeted therapies (8, 9),
their utility in advanced cancers has so far
been limited due to an almost inevitable
tumor recurrence even after successful ini-
tial response [reviewed in Ref. (6, 10, 11)].
The escape mechanisms underlying the
inherent and acquired resistance to tar-
geted therapies include feedback activa-
tion of signaling pathways with redundant
functions (12), co-occurrence of muta-
tions in other genes involved in synergis-
tic interactions with the target gene (13),
or emergence of subclones with secondary
mutations coding for resistant versions of
drug targets (14). Global profiling of cancer
genomes has enabled the stratification of
major cellular pathways involved in the
development of therapeutic resistance in
different types of cancer. Providing a mole-
cular explanation of the limited efficacy of
targeted monotherapies, cancer genomics
studies reveal a high degree of functional
redundancy between oncogenic driving
events [reviewed in Ref. (7, 15)].
New generation sequencing method-
ologies while enabling to identify genomic
alterations associated with different types
of cancer with an unprecedented com-
pleteness also revealed the high degree of
genetic diversity existing not only between
different types of cancer but also between
individual tumors of the same histo-
type [reviewed in Ref. (16, 17)]. A broad
range of phenomena encompassed in the
term “tumor heterogeneity” include (epi)
genetic, phenotypic, and gene expression
pattern diversity across different types of
cancer, between different tumors of the
same histotype (interpatient heterogene-
ity), between different tumors from the
same patient (primary tumor or metasta-
sis), or within the same tumor (intratumor
heterogeneity). Intratumor heterogeneity
manifests in spatial and temporal pat-
terns of genetic, phenotypic, and func-
tional diversity (18). There is a grow-
ing evidence of intratumor heterogene-
ity in different types of cancers including
breast cancer (19), renal carcinomas (20,
21), and glioblastomas (22). Mechanisms
underlying intratumor heterogeneity can
be broadly divided into those that are
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powered by genomic instability or non-
mutational mechanisms. The latter include
stochastic variations in cellular responses
between genetically identical tumor cells,
modulation of cellular responses by tumor
microenvironment,and/or phenotypic and
functional plasticity contributed by can-
cer stem cells (CSCs) [reviewed in Ref.
(17, 23)]. Genomic instability defined as
progressive mutagenic process accompany-
ing neoplastic growth is the major mech-
anism of generating new mutations. Less
well-characterized mechanisms include
genome doubling (24) and rare cataclysmic
genomic rearrangements resulting in mas-
sive genomic rearrangements (25). Accord-
ing to the clonal evolution model, persis-
tent changes in tumor genomes generate
genetically and functionally distinct clones
that may occupy different geographic ter-
ritories within the tumor. There are many
lines of evidence for the spatial patterns of
intratumor heterogeneity in advanced can-
cers. In glioblastomas (glioblastoma multi-
forme, GBM), distinct patterns of genomic
alterations and gene expression signatures
can be found in different regions within
the same tumor (22). Strikingly, molecular
signatures that were previously thought to
be associated with clinically distinct sub-
types of GBM (26, 27) were found to
co-exist within the same tumor (22). Sim-
ilarly, more than 60% of all somatic muta-
tions identified through a multi-region
genetic analysis in renal carcinoma were
found spatially separated within the same
tumor and not detectable in every tumor
region analyzed (20). These findings indi-
cate that different sampling strategies can
strongly impact the interpretation of mol-
ecular profiling data obtained with single
tumor samples and emphasize the need
for suitable methodologies that would take
into account the spatiotemporal patterns of
intratumor heterogeneity.
These considerations are of particular
relevance in the context of the CSC hypoth-
esis, which postulates that CSCs constitute
only a minor fraction of tumor cells capa-
ble of initiating tumor growth [reviewed in
Ref. (1, 28)]. In light of the findings that dif-
ferent types of tumor cells can be geograph-
ically separated within the tumor (20,22), it
is possible that CSCs may be unevenly dis-
tributed throughout the tumor. It should
be noted that in many studies, the tumori-
genic potential is compared between CSCs
and non-CSC tumor cells isolated from
a single tumor region. Thus, the rela-
tive proportion of CSCs may vary not
only between different tumor types (CSC-
derived malignancies vs. non-CSC tumors)
but also within the tumors that comply
with the CSC paradigm, depending on the
tumor region analyzed. The CSC hypoth-
esis postulates that CSC is the only type
of tumor cells (in CSC-derived tumors)
that possesses the propensity to initiate and
maintain tumor growth (29, 30). However,
in the light of consideration that a single
tumor region may not be representative
of the whole tumor (20, 22), it cannot be
excluded that highly tumorigenic non-CSC
may have been missed in analyses using
single tumor specimens. In such a case,
the conclusion that non-CSCs have gen-
erally lower tumorigenicity compared to
CSCs would have been misleading due to
a sampling bias.
The fact that genetically (and function-
ally) heterogeneous types of cancer cells
can be separated spatially within a tumor
raises several important questions con-
cerning the identity of tumor clones that
are capable of escaping from anti-cancer
treatments and repopulating the tumor.
There is some evidence that exposure to
therapy may influence the dynamics of
clonal repopulation and lead to the alterna-
tion of clonal dominance as a consequence
of treatment. For example,by applying next
generation sequencing to compare somatic
mutations in matched pairs of de novo
and recurrent AMLs, it was established
that a minor AML clone underrepresented
in the primary tumor became dominant
in recurrent tumors as a consequence of
chemotherapy (31). Similarly, cytogenet-
ics and gene expression analyses in a series
of sequential samples of multiple myeloma
from the same patient treated with different
chemotherapy regimens have revealed that
tumor relapse was associated with the pref-
erential outgrowth of a minor clone (32).
In the emerging scenario, the dominance
of clone A in untreated tumors can be lost
during anti-cancer therapy (provided that
clone A fulfils the criteria for the target cell)
whereas clone B lacking the molecular tar-
get can become dominant even if it was
underrepresented in untreated tumors.
The realization that intratumor hetero-
geneity poses one of the major challenges
to overcome resistance to anti-cancer
therapy raises a number of questions:
are there common molecular denomi-
nators underlying resistance to different
types of therapy? Is there an interaction
between different populations of cancer
cells residing in the same or different geo-
graphic regions of the same tumor? What
is the impact of different types of anti-
cancer therapy in the emergence of resis-
tant clones? To address these issues, there
is a need of suitable methodologies that
would take into account the spatiotempo-
ral patterns of intratumoral diversity. It
has been proposed that multiple sampling
analyses of multiple regions from matched
pairs of untreated and recurrent tumors
would be required to assess the impacts
of intratumoral diversity on the develop-
ment of resistance to anti-cancer therapies
(22). Such an approach may have limited
applicability in those tumors for which
serial sampling is difficult to achieve. For
example, serial tumor sampling in post-
operated GBM is likely to be a challenge
considering that repeat surgery, as a treat-
ment option, is possible only for 15–45%
of patients depending on age, neurologic
performance, and extent of resection dur-
ing the first operation (33). Considering
that multisampling is a much more realis-
tic task during the first surgery, a combined
approach based on establishing heteroge-
neous primary cultures from multisampled
untreated tumors and selecting from them
therapy-resistant clones in vitro might be
more feasible. Such an approach has the
advantage of reducing the variability in
treatment conditions and dissecting the
effects of single and combined treatments.
By comparing treatment responses in dif-
ferent types of cancer cells from the same
tumor should allow to improve predictions
on the efficacy of a particular treatment
scheme in a particular tumor.
It should be noted that the degree
of intratumoral heterogeneity may not
necessarily reflect an enhanced malignant
potential. It is believed that a considerable
portion of new mutations arising in the
course of tumor evolution are passenger
mutations (7). In such a case, the num-
ber of clinically relevant oncogenic driver
mutations may still be within the range
attackable by combinatorial treatment reg-
imens using different therapies applied
either simultaneously or sequentially. Also,
the growing realization that tumor growth
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before, during, or after treatment can be
driven by molecularly distinct populations
of cells (31, 32) may have important impli-
cations for the rational design of combina-
torial therapy regimens that would match
the dynamically changing cellular and mol-
ecular composition of the tumor. Unfor-
tunately, increased toxicity poses a general
problem impeding the benefits of com-
bined therapies. In this regard, alternating
targeted therapies using agents with non-
overlapping toxicity profiles may provide
a means to achieve additive anti-tumor
effects without increasing overall toxicity.
The efficacy of alternating therapies guided
by “real-time” molecular assessments has
been demonstrated for metastatic lung
tumor originating from adenocarcinoma
of the tongue (34). In this study, a clinical
benefit could be reached by applying alter-
nating treatments with different therapeu-
tic agents whose effectiveness was inferred
by comparing whole-genome and RNA
profiles of untreated and recurrent tumors.
The emerging scenario of recurrent
tumor growth reveals key roles of intra-
tumoral heterogeneity in intrinsic and
acquired resistance to cytotoxic and
targeted therapies. Understanding spa-
tiotemporal patterns and dynamics of
intratumoral heterogeneity before and
during therapy is crucial for the ability to
design individual-tailored treatment regi-
mens best suited to a particular molecular
context.
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